Agile Therapeutics Inc (NASDAQ:AGRX) shares traded down 19.7% on Thursday . The stock traded as low as $0.61 and last traded at $0.53. 33,321 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 1,322,423 shares. The stock had previously closed at $0.66.
Several research analysts have recently weighed in on the company. HC Wainwright set a $4.00 price target on Agile Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Agile Therapeutics has an average rating of “Buy” and an average target price of $4.00.
The company has a market capitalization of $12.60 million, a price-to-earnings ratio of -0.82 and a beta of 1.43.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. Sell-side analysts anticipate that Agile Therapeutics Inc will post -0.61 earnings per share for the current year.
In related news, insider Life Sciences Maste Perceptive sold 298,628 shares of the company’s stock in a transaction on Thursday, July 26th. The stock was sold at an average price of $0.30, for a total transaction of $89,588.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.30% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. A.R.T. Advisors LLC increased its position in Agile Therapeutics by 82.3% during the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after acquiring an additional 29,995 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Agile Therapeutics by 76.3% during the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 343,290 shares during the last quarter. Institutional investors own 52.00% of the company’s stock.
About Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
See Also: Trading Strategy Methods and Types
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.